Form 4: Organon & Co. Executive Vittorio Nisita Reports Stock Option Grant and RSU Vesting

Vittorio Nisita, Head of Global Business Services at Organon & Co., reports the vesting of restricted stock units (RSUs) and the grant of stock options.

Summary

• On March 31, 2025, Vittorio Nisita, Head of Global Business Services at Organon & Co., reported transactions related to Organon common stock.
• These transactions include the vesting of several tranches of Restricted Stock Units (RSUs) granted in previous years (2022, 2023, and 2024).
• Nisita also received a grant of 123,762 stock options, which vest in three equal installments starting March 31, 2026.
• Additionally, Nisita was granted 25,184 RSUs that will vest in three equal installments beginning March 31, 2026.
• The vesting of RSUs resulted in the acquisition of common stock, while a portion of the shares were disposed of to cover tax obligations at a price of $14.51 per share.
• Following these transactions, Nisita directly owns 43,821.539 shares of Organon common stock, 123,762 stock options, and 25,184 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing primarily reports routine insider transactions related to equity compensation. There are no explicit positive or negative implications for the company's performance.

Positives

• The grant of stock options and RSUs to a key executive like Vittorio Nisita aligns his interests with those of the shareholders.
• The vesting schedule of the options and RSUs encourages long-term commitment from the executive.

Future Outlook

The reported transactions indicate future vesting dates for stock options and RSUs, suggesting continued equity-based compensation for the reporting person.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the equity-based compensation of key executives.

Comparison to Industry Standards

• Equity compensation practices vary across the pharmaceutical industry, but stock options and RSUs are common tools for aligning executive incentives with shareholder value.
• Companies like Pfizer, Merck, and Johnson & Johnson also utilize similar equity-based compensation plans for their executives.
• The vesting schedules and grant sizes are generally benchmarked against peer companies to ensure competitiveness and retention.

Stakeholder Impact

• Shareholders may view the equity-based compensation as a way to align management's interests with the company's long-term performance.
• Employees may see the executive's compensation as a reflection of the company's commitment to rewarding its leadership.

Key Dates

Keywords

Organon & Co., Vittorio Nisita, stock options, RSU, Restricted Stock Units, Form 4, vesting, common stock, insider trading